Vertex Pharmaceuticals Inc
VRTX477.920USD
+19.110+4.17%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
121.37B시가총액
33.40P/E TTM
자세한 내용은 Vertex Pharmaceuticals Inc 회사
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Vertex Pharmaceuticals Inc 정보
종목 코드 VRTX
회사 이름Vertex Pharmaceuticals Inc
상장일Jul 24, 1991
CEOKewalramani (Reshma)
직원 수6100
유형Ordinary Share
회계 연도 종료Jul 24
주소50 Northern Avenue
도시BOSTON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02210
전화16173416393
웹사이트https://www.vrtx.com/
종목 코드 VRTX
상장일Jul 24, 1991
CEOKewalramani (Reshma)
Vertex Pharmaceuticals Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
90.67K
+38857.00%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+5000.00%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
44.00K
+11333.00%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
33.48K
+9012.00%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
33.05K
+7249.00%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
24.37K
+9068.00%
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
22.93K
+6800.00%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
6.32K
-800.00%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.57K
-266.00%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+796.00%
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
90.67K
+38857.00%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+5000.00%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
44.00K
+11333.00%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
33.48K
+9012.00%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
33.05K
+7249.00%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
24.37K
+9068.00%
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
TRIKAFTA
2.65B
86.26%
ALYFTREK
247.00M
8.03%
Other CF products
175.80M
5.71%
지역별USD
이름
수익
비율
United States
1.98B
64.24%
Europe
836.90M
27.20%
Other
263.20M
8.56%
사업별
지역별
사업별USD
이름
수익
비율
TRIKAFTA
2.65B
86.26%
ALYFTREK
247.00M
8.03%
Other CF products
175.80M
5.71%
주식 보유 통계
마지막 업데이트: Sat, Nov 15
마지막 업데이트: Sat, Nov 15
주주
주주 유형
주주
주주
비율
Capital World Investors
10.21%
The Vanguard Group, Inc.
9.45%
Capital Research Global Investors
6.52%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Investment Management (US)
4.57%
기타
63.53%
주주
주주
비율
Capital World Investors
10.21%
The Vanguard Group, Inc.
9.45%
Capital Research Global Investors
6.52%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Investment Management (US)
4.57%
기타
63.53%
주주 유형
주주
비율
Investment Advisor
60.46%
Investment Advisor/Hedge Fund
27.86%
Pension Fund
2.37%
Research Firm
2.35%
Bank and Trust
2.10%
Sovereign Wealth Fund
1.50%
Hedge Fund
1.14%
Individual Investor
0.19%
Insurance Company
0.06%
기타
1.96%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
2986
248.55M
97.96%
-4.86M
2025Q3
2933
249.27M
98.24%
-2.14M
2025Q2
2933
252.71M
98.56%
+2.47M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Capital World Investors
25.91M
10.21%
-2.82M
-9.82%
Sep 30, 2025
The Vanguard Group, Inc.
24.10M
9.5%
+240.67K
+1.01%
Sep 30, 2025
Capital Research Global Investors
16.55M
6.52%
+444.99K
+2.76%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
14.47M
5.7%
+317.50K
+2.24%
Sep 30, 2025
State Street Investment Management (US)
11.61M
4.57%
-169.23K
-1.44%
Sep 30, 2025
Geode Capital Management, L.L.C.
5.97M
2.35%
+45.00K
+0.76%
Sep 30, 2025
Invesco Capital Management (QQQ Trust)
5.69M
2.24%
+318.09K
+5.92%
Dec 31, 2025
Wellington Management Company, LLP
4.77M
1.88%
-41.34K
-0.86%
Sep 30, 2025
Capital International Investors
4.69M
1.85%
+2.05M
+77.89%
Sep 30, 2025
AllianceBernstein L.P.
4.52M
1.78%
+144.27K
+3.30%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Fri, Dec 5
마지막 업데이트: Fri, Dec 5
이름
비율
VanEck Biotech ETF
9.71%
ProShares Ultra Nasdaq Biotechnology
8.83%
Invesco Nasdaq Biotechnology ETF
8.76%
iShares Biotechnology ETF
7.43%
Invesco Biotechnology & Genome ETF
5.35%
Natixis Loomis Sayles Focused Growth ETF
4.48%
First Trust NASDAQ Pharmaceuticals ETF
4.23%
First Trust NYSE Arca Biotechnology Index Fund
3.5%
Franklin Genomic Advancements ETF
3.33%
Simplify Health Care ETF
3.25%
더 보기
VanEck Biotech ETF
비율9.71%
ProShares Ultra Nasdaq Biotechnology
비율8.83%
Invesco Nasdaq Biotechnology ETF
비율8.76%
iShares Biotechnology ETF
비율7.43%
Invesco Biotechnology & Genome ETF
비율5.35%
Natixis Loomis Sayles Focused Growth ETF
비율4.48%
First Trust NASDAQ Pharmaceuticals ETF
비율4.23%
First Trust NYSE Arca Biotechnology Index Fund
비율3.5%
Franklin Genomic Advancements ETF
비율3.33%
Simplify Health Care ETF
비율3.25%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
